Metformin


Literature identifierStudy typeTest dosageEffective dosageEndocrine-mediated endpointsSystems-level perturbations
PMID:33002602IVTH0.005 - 0.007 M 0.005 - 0.007 MDecreased androstenedione levelsReproductive endocrine-mediated perturbations
IVTH0.005 M 0.005 MIncreased pregnenolone levelsReproductive endocrine-mediated perturbations
IVTH0.005 M 0.005 MDecreased testosterone levelsReproductive endocrine-mediated perturbations
IVTH0.005 - 0.007 M 0.005 - 0.007 MDecrease in cortisol levelsNeurological endocrine-mediated perturbations
IVTH0.005 M 0.005 MDecreased Dehydroepiandrosterone (DHEA) levelsMetabolic endocrine-mediated perturbations
IVTH0.005 - 0.007 M 0.005 - 0.007 MDecreased cortisone levelsNeurological endocrine-mediated perturbations
IVTH0.005 - 0.007 M 0.005 - 0.007 MIncreased progesterone levelsReproductive endocrine-mediated perturbations
IVTH0.005 - 0.007 M 0.005 - 0.007 MIncreased 17-OH-progesterone levelsReproductive endocrine-mediated perturbations
IVTH0.001 - 0.007 M 0.001 - 0.007 MDecreased estrone levelsReproductive endocrine-mediated perturbations

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.